Steven Pieper, who serves as the Chief Financial Officer for Xeris Biopharma Holdings Inc. (NASDAQ:XERS), executed a series of sales totaling 45,000 shares of common stock during the first week of July 2026. The transactions, which generated approximately $383,176 in proceeds, were facilitated through a pre-arranged Rule 10b5-1 trading plan that Pieper adopted on August 18, 2025. This structured approach to selling shares is typically utilized to manage executive liquidity while complying with securities regulations.
On July 6, 2026, Pieper divested 17,400 shares at a price of $8.50 per share, resulting in a total value of $147,900. The following day, July 7, 2026, he sold an additional 27,600 shares. These subsequent transactions were executed at a weighted average price of $8.5245, with individual share prices varying between $8.50 and $8.60. The second tranche of sales amounted to roughly $235,276.
Following these dispositions, Pieper’s direct ownership in Xeris Biopharma stands at 1,366,053 shares. This total includes 2,113 shares acquired on June 30, 2026, under the company’s 2018 Employee Stock Purchase Plan. The stock currently trades at $8.95, a level that InvestingPro analysis indicates is above its Fair Value, placing it on the platform’s Most Overvalued list. The stock has delivered a strong 78% return over the past year, according to InvestingPro data.
In broader corporate developments, Xeris Biopharma reported robust financial results for the first quarter of 2026. Total revenue increased by 38% year-over-year to $83.1 million. Despite a slight miss on revenue forecasts, the company exceeded earnings expectations with an earnings per share of $0.01. Additionally, the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering Xeris’ Keveyis product, which is used in the treatment of primary periodic paralysis, with the patent protection extending through 2039.
The company also announced plans to retire approximately $23 million in convertible notes due in 2028, involving cash payments and the issuance of common stock based on a 21-day volume-weighted average price. In corporate governance developments, Xeris appointed CEO John Shannon as Chair of the Board, effective July 1, 2026, while adding Nerissa Kreher, M.D., to its Board of Directors. These developments reflect ongoing strategic and financial maneuvers by the company.
The stock currently trades at $8.95, which InvestingPro analysis suggests is above its Fair Value, placing it on the platform’s Most Overvalued list. In other recent news, Xeris Biopharma Holdings reported robust financial results for the first quarter of 2026, with total revenue increasing by 38% year-over-year to $83.1 million. Despite a slight miss on revenue forecasts, the company exceeded earnings expectations with an earnings per share of $0.01. Additionally, the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering Xeris’ Keveyis product, which is used in the treatment of primary periodic paralysis, with the patent protection extending through 2039. Xeris PharmaceuticalsFollowAnalyze XERSIncluded in our AI-picked strategies·Review strategies8.95▲+0.580(+6.93%)Closed·15:59:59·USD8.940.000(0.00%)After Hours·17:19:571D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:008.258.58.759Analyze XERSThe company also announced plans to retire approximately $23 million in convertible notes due in 2028, involving cash payments and the issuance of common stock based on a 21-day volume-weighted average price. In corporate governance developments, Xeris appointed CEO John Shannon as Chair of the Board, effective July 1, 2026, while adding Nerissa Kreher, M.D., to its Board of Directors. These developments reflect ongoing strategic and financial maneuvers by the company.